Clinical Experience with the Baerveldt Glaucoma Drainage Implant

doi:10.1016/S0161-6420(95)30871-8

Ophthalmology

Volume 102, Issue 9, September 1995, Pages 1298-1307

https://doi.org/10.1016/S0161-6420(95)30871-8 Get rights and content

Purpose: To assess clinical outcomes in patients who were treated with the Baerveldt glaucoma drainage implant.

Methods: The authors performed a retrospective multicenter study of 100 patients (103 eyes) with medically uncontrollable glaucomas who underwent a one-stage implantation with either the 200-, 250-, 350-, or 500-mm2 Baerveldt implant. The authors defined surgical success as 5 mmHg less than intraocular pressure less than 22 mmHg without additional glaucoma surgery and without loss of light perception.

Results: With a mean follow-up of 13.6 ± 0.9 months (range, 4-37 months), 74 eyes (71.8%) had successful outcomes. Cumulative life-table success rates were 90.3% at 3 months (n = 103), 72.6% at 6 months (n = 84), and 60.3% at 24 months (n = 34). Intraocular pressure (IOP) was reduced from a mean of 38.5 ± 1.4 mmHg with 2.2 ± 0.1 antiglaucoma medications to 15.1 ± 0.8 mmHg (P < 0.0005) with 0.5 ± 0.1 antiglaucoma medications (P < 0.0005). Visual acuity was improved or remained within one line of the preoperative visual acuity in 90 eyes (87.4%). Complications occurred in 74 eyes (71.8%). A significant portion of these complications (45%) was transient, resolving without any intervention. Only 8% were serious sight-threatening complications. The most common complications included shallow anterior chamber or hypotony (32%), choroidal effusion or hemorrhage (20.4%), corneal decompensation or edema (17.5%), hyphema (14.1 %), and tube obstruction (12.6%).

Conclusion: The Baerveldt implant is effective in lowering the IOP in patients with intractable glaucomas. Hypotony and other complications are common, which also have been reported in other nonvalved glaucoma drainage implants. However, the majority of these complications did not affect surgical outcome.

References (50)

SS Schocket et al.
Anterior chamber tube shunt to an encircling band in the treatment of neovascular glaucoma and other refractory glaucomas: a long-term study
Ophthalmology
(1985)
SS Schocket et al.
Anterior chamber tube shunt to an encircling band in the treatment of neovascular glaucoma
Ophthalmology
(1982)
T Krupin et al.
Filtering valve implant surgery for eyes with neovascular glaucoma
Am J Ophthalmol
(1980)
MA Lloyd et al.
Initial clinical experience with the Baerveldt implant in complicated glaucomas
Ophthalmology
(1994)
MA Lloyd et al.
Intermediateterm results of a randomized clinical trial of the 350- versus the 500-mm² Baerveldt implant
Ophthalmology
(1994)
SL Smith et al.
Early clinical experience with the Baerveldt 350-mm² glaucoma implant and associated extraocular muscle imbalance
Ophthalmology
(1993)
PA Sidoti et al.
Epithelial ingrowth and glaucoma drainage implants
Ophthalmology
(1994)
S Melamed et al.
Postoperative complications after Molteno implant surgery
Am J Ophthalmol
(1991)
DS Minckler et al.
Clinical experience with the single-plate Molteno implant in complicated glaucomas
Ophthalmology
(1988)
MA Lloyd et al.
Clinical experience with the single-plate Molteno implant in complicated glaucomas: update of a pilot study
Ophthalmology
(1992)

DK Heuer et al.

Which is better? One or two? A randomized clinical trial of single-plate versus double-plate Molteno implantation for glaucomas in aphakia and pseudophakia

Ophthalmology

(1992)

T Krupin et al.

Valve implants in filtering surgery

Am J Ophthalmol

(1976)

T Krupin et al.

Filtering valve implant surgery for eyes with neovascular glaucoma

Am J Ophthalmol

(1980)

T Krupin et al.

Long-term results of valve implants in filtering surgery for eyes with neovascular glaucoma

Am J Ophthalmol

(1983)

PS Fellenbaum et al.

Krupin disk implantation for complicated glaucomas

Ophthalmology

(1994)

RA Hitchings et al.

Use of onepiece valved tube and variable surface area explant for glaucoma drainage surgery

Ophthalmology

(1987)

T Krupin et al.

A long Krupin-Denver valve implant attached to a 180 degrees scleral explant for glaucoma surgery

Ophthalmology

(1988)

PJ McDonnell et al.

Molteno implant for control of glaucoma in eyes after penetrating keratoplasty

Ophthalmology

(1988)

WE Beebe et al.

The use of Molteno implant and anterior chamber tube shunt to encircling band for the treatment of glaucoma in keratoplasty patients

Ophthalmology

(1990)

RA Hill et al.

Molteno implantation for glaucoma in young patients

Ophthalmology

(1991)

RP Wilson et al.

Aqueous shunts. Molteno versus Schocket

Ophthalmology

(1992)

A Mermoud et al.

Molteno tube implantation for neovascular glaucoma: long-term results and factors influencing the outcome

Ophthalmology

(1993)

AS Williams

Setons in glaucoma surgery

AC Molteno

The optimal design of drainage implants for glaucoma

Trans Ophthalmol Soc N Z

(1981)

MF Lieberman et al.

Drainage implant surgery for refractory glaucoma

Int Ophthalmol Clin

(1990)

Cited by (187)

The History of Tube Shunts
2024, Advances in Ophthalmology and Optometry
Effect of Lens Status on the Outcomes of Glaucoma Drainage Device Implantation
2024, Ophthalmology Glaucoma
To assess the effect of lens status and cataract surgery on glaucoma drainage device (GDD) efficacy.
Retrospective cohort study.
Two hundred and forty-three eyes of 216 patients that underwent GDD implantation with $\geq$ 1 follow-up visit within 3 years postoperatively. Exclusion criteria included GDD combined with other ophthalmic procedures. 90%–94% of GDDs were Ahmed implants; 83%–90% had adjunctive mitomycin-C.
Outcomes were compared between phakic eyes (group A), eyes phakic at time of implantation but subsequently underwent cataract surgery within 3 years (group B), and pseudophakic eyes (group C). Outcomes were measured at 1, 3, 6, 12, 24, and 36 months after tube shunt implantation. Multivariable regression models were performed, adjusting for baseline characteristics.
Intraocular pressure (IOP) after GDD implantation. Secondary outcomes included change in visual acuity (VA), number of glaucoma eye drops, and rate of failure, defined as additional glaucoma surgery, vision decrease to no light perception, or IOP persistently ≤ 5 mmHg or > 21 mmHg or not reduced from baseline by 20%.
There were 65 eyes in group A, 52 in group B, and 126 in group C. Within group B, cataract surgery was performed at a mean of 1.3 ± 0.7 years after GDD implantation. There were no statistically significant differences in mean IOP or medications between the 3 groups at all time points up to 3 years postoperatively. Significant improvement in VA was noted in groups A and B compared to group C at 6 months, 1 year, and 2 years after implantation; however, by postoperative year 3, change in VA was similar across groups. There were no significant differences in the failure rate amongst groups (P = 0.68). IOP and medications up to 12 months after cataract surgery were similar compared to preoperative baseline. Group B had significantly more short-term (P = 0.02) and long-term (P < 0.001) postoperative complications than groups A or C, driven primarily by hypotony.
There were no differences in IOP, glaucoma medications, or rate of failure 3 years after GDD implantation based on lens status or after undergoing subsequent cataract surgery. These results may inform the management of patients with co-existing glaucoma and cataract.
The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Early Intraocular Pressure Control Via Capsule Revision of a Failed Valved Aqueous Shunt During Concurrent Placement of a Nonvalved Aqueous Shunt
2022, Ophthalmology Glaucoma
To describe the novel strategy of performing a concurrent capsule revision of a failed pre-existing valved aqueous shunt with implantation of an additional nonvalved aqueous shunt for early postoperative intraocular pressure (IOP) control.
Case report of a single patient.
An 87-year-old man with severe primary open-angle glaucoma in both eyes presented to our clinic. His pseudophakic left eye had a failed superonasal trabeculectomy and an encapsulated superotemporal Ahmed FP7 (New World Medical) aqueous shunt in the anterior chamber. He had previously undergone micropulse cyclophotocoagulation 3 times and excisional goniotomy. Visual acuity in his left eye was 20/30, and IOP was 24 mmHg on 4 topical IOP-lowering medications. An inferonasal Baerveldt 350 (Advanced Medical Optics) aqueous shunt was placed with concurrent revision of the Ahmed capsule. A large block of capsule tissue was excised from the surface of the plate, and 20 mg of subtenon triamcinolone acetonide (Kenalog, Bristol-Myers Squibb) was injected overlying the plate. His IOP ranged between 6 and 15 mmHg in the immediate postoperative period. There were no hypotony-associated complications at any time point. At postoperative month 18, his IOP was 10 mmHg on zero medications.
In patients with a failed valved aqueous shunt undergoing an additional nonvalved aqueous shunt, a concurrent capsule revision of the valved aqueous shunt can provide early IOP lowering before the nonvalved tube opens.
Tube Versus Trabeculectomy IRIS registry 1-Year Composite Outcome Analysis with Comparisons to the Randomized Controlled Trial
2021, American Journal of Ophthalmology
This study compared 1-year results for the composite treatment outcome from the Tube Versus Trabeculectomy (TVT) randomized controlled trial (RCT) to those from an IRIS^Ⓡ (Intelligent Research In Sight) Registry cohort of analogous eyes.
Retrospective clinical study with comparison to an RCT.
Subjects’ eyes in the IRIS Registry received either a glaucoma drainage implant (tube) or underwent trabeculectomy after a previous trabeculectomy and/or cataract extraction and had data for 1-year follow-up analyses.
Eyes were classified as failing if they had hypotony (intraocular pressure (IOP) ≤5 mm Hg) or inadequate IOP control (IOP >21 mm Hg or not reduced at least 20% below baseline) on 2 consecutive follow-up visits after 3 months, a reoperation for glaucoma, or no light perception vision and as successful otherwise. Failure risk was compared by treatment, demographic, and clinical variables and was compared to analogous failure risks from the TVT RCT.
The TVT IRIS Registry cohort included 419 eyes, 236 tube eyes (56.3%) and 183 trabeculectomy eyes (43.7%). In this cohort, there was no significant failure risk difference (12.3% for tube eyes and 16.4% for trabeculectomy eyes, P = 0.231). Comparing the studies, there was a significantly greater risk of failure in the TVT IRIS Registry tube eyes than in the TVT RCT tube eyes (3.8%; P <.001). Reasons for treatment failure included reoperations for glaucoma (none in the TVT RCT at 1 year).
Our results were different from those in the TVT RCT. Possible reasons include non-Baerveldt tubes, greater severity among tube eyes, and practice patterns that reflect real-world data, which are different than those in RCTs.
Corneal Parameters after Tube-Shunt Implantation through the Ciliary Sulcus
2021, Ophthalmology Glaucoma
To monitor bilateral corneal parameters after unilateral Baerveldt 350 tube-shunt implantation (Advanced Medical Optics, Santa Ana, CA) through the ciliary sulcus.
Retrospective, interventional case series.
Patients from 1 private glaucoma practice with severe uncontrolled glaucoma treated with sulcus tube-shunt implantation in 1 pseudophakic eye.
Specular microscopy data were collected before and after unilateral sulcus tube-shunt implantation from the surgical and the glaucomatous fellow eyes.
Central corneal endothelial cell density (CECD), coefficient of variation (CV), percent of hexagonal cells, central corneal thickness (CCT), intraocular pressure (IOP), IOP-lowering medications, visual acuity, and complications.
Forty-six patients (mean age, 69.9 years; standard deviation [SD], 4.6 years; range, 20–88 years; male gender, 41.3%) were identified. After surgery, IOP and the number of IOP-lowering medications decreased significantly by 42.3% (P < 0.0001) and 32.1% (P < 0.0001), respectively, in the surgical eye group. Preoperative CECD measured 1807 cells/mm² (SD, 172 cells/mm²) and 1825 cells/mm² (SD, 172 cells/mm²) in the surgical and fellow eyes, respectively (P = 0.92), and compared with baseline, it decreased by 8.6% (P = 0.17) and 3.1% (P = 0.65), respectively, by 24 months. Preoperative CV, percent of hexagonal cells, and CCT were similar in both groups and remained stable. All corneal parameters remained unchanged in a subgroup of 15 patients with low preoperative CECD (1273 cells/mm²; SD, 99 cells/mm²). Best-corrected visual acuity remained stable in both groups. Hyphema occurred in 23.9% of the surgical eyes and resolved with no intervention. We found no sight-threatening complications or corneal failures during follow-up.
Tube-shunt implantation through the ciliary sulcus in pseudophakic eyes appears relatively safe to the corneal endothelium, demonstrating a small and nonsignificant decline in central CECD compared with baseline and with glaucomatous fellow eyes. No significant disruption to corneal endothelial cell morphologic features, increased corneal thickness, or corneal failures were found during the 24-month follow-up period. A prospective head-to-head comparison to assess the effects of the various methods of tube-shunt implantation on the corneal endothelium is needed.
Evaluation of pericardium patch graft thickness in patients with Ahmed glaucoma valve implantation: an anterior segment OCT study
2024, Japanese Journal of Ophthalmology

View all citing articles on Scopus

: Supported in part by the Massachusetts Lions Eye Research Fund, Worcester, Massachusetts.

View full text